New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 20, 2012
12:43 EDTMNTAMomenta Pharma petition for rehearing denied by Court of Appeals
Momenta Pharmaceuticals announced that the United States Court of Appeals for the Federal Circuit denied its request for a rehearing en banc to reconsider its three-judge panel opinion in the case of Momenta Pharmaceuticals vs. Amphastar Pharmaceuticals, Inc. The request for all active judges of the court to reconsider a panel decision, known as rehearing en banc, is only granted upon a majority vote. "We will continue to pursue our appellate options and we plan to file a petition for certiorari, asking the Supreme Court to review this case," said Craig Wheeler, president and CEO of Momenta.
News For MNTA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 25, 2015
15:02 EDTMNTAMylan says USPTO institutes IPR of two Copaxone patents
Subscribe for More Information
14:40 EDTMNTATeva Copaxone patents to be reconsidered by regulators, Bloomberg says
August 20, 2015
07:31 EDTMNTAMomenta shares offer 'significant opportunity,' says Bernstein
Bernstein analyst Ronny Gal sees a "significant opportunity" in shares of Momenta Pharmaceuticals over the next few months. Copaxone sales should prove durable as a competing approval is unlikely until mid-2016, Gal tells investors in a research note. The analyst sees limited share downside before year-end and raised his price target for the stock to $31. He keeps an Outperform rating on Momenta.
August 19, 2015
10:05 EDTMNTAHigh option volume stocks
High option volume stocks: MNTA TUR ITB CLR HILL DV AU XLNK AEO CYBR

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use